BACKGROUND: The characteristics of red blood cell (RBC) products change after 2 weeks of cold storage. It is unclear whether older RBCs affect mortality after liver transplantation. This retrospective cohort study aimed to evaluate the association between the age of transfused RBCs and death after living donor liver transplantation (LDLT). STUDY DESIGN AND METHODS: Of 200 recipients who underwent LDLT, 118 who received RBCs with a mean storage duration of less than 10 days (shorter storage group) were compared with 82 with an RBC mean storage duration of more than 14 days (longer storage group). Key exclusion criteria were transfusion of very fresh RBCs stored for less than 4 days and transfusion of old RBCs in recipients of the shorter storage group. The primary outcome was posttransplant overall death. Survival analysis was performed using the Cox model. RESULTS: Mean RBC storage duration was 7 days in the shorter storage group and 17 days in the longer storage group. Death probability at 1, 2, and 5 years posttransplant was 5.1%, 7.6%, and 13.6% in the shorter storage group, respectively, and 6.1%, 8.5%, and 13.5% in the longer storage group. Death risk was comparable between the two groups in univariable (hazard ratio [HR] 1.00, 95% confidence interval [CI], 0.47-2.16, p = 0.991) and multivariable (HR 1.07, 95% CI, 0.46-2.50, p = 0.882) analyses. Graft failure risk was also comparable (HR 1.04, 95% CI, 0.50-2.18, p = 0.916). Hepatocellular carcinoma recurrence probability at 1, 2, and 5 years was 10.8%, 15.4%, and 23.1%, respectively, in the shorter storage group and 11.4%, 15.9%, and 20.7% in the longer storage group (HR 0.84, 95% CI, 0.37-1.89, p = 0.670). No significant differences were observed regarding graft regeneration/function, vascular/biliary complications, acute kidney injury, surgical site infection, or rejection (p > 0.05). CONCLUSIONS: No evidence was found that transfusion of old RBCs contributes to death after LDLT. (2018). Longer storage of red blood cells does not affect mortality in transfused liver transplant recipients. Transfusion, 58 (11):2529-2537.
Therefore, we aimed to reappraise the risk of old RBCs in liver transplant recipients to 23 determine whether there is a clinical benefit from avoiding use of such RBCs.
MATERIALS AND METHODS
1 Subjects and data collection 2 We initially screened the records of 480 patients who underwent their first adult-to-adult 3 living donor liver transplantation between January 2006 and May 2014 in our hospital and 4 received at least one RBC unit during the perioperative period, which was defined as the time 5 during surgery and within 2 weeks after transplantation. 6 Of these recipients, we excluded 6 135 recipients who received at least one RBC unit stored for <4 days. 6 Among the remaining 7 358 recipients, 111 recipients who received RBCs with a mean storage duration of 10-14 8 days were further excluded to increase the sensitivity of potential effects of older RBCs and 9 decrease the risk of type II error by increasing the gap in RBC storage duration between study 10 groups. Fourteen recipients who received RBCs with a mean storage duration of <10 days but 11 who also received at least one RBC unit stored for >14 days were further excluded along with 12 11 recipients who received at least one RBC unit prior to surgery during admission. Nine 13 recipients who were confirmed via pathology to have hepatocellular carcinoma (HCC) 14 macrovascular invasion were further excluded due to the very high risk of death from HCC 15 recurrence. 6, 21 Among the remaining 200 recipients, 118 recipients who received RBCs with 16 a mean storage duration of <10 days were included in shorter-storage group and 82 recipients 17 who received RBCs with a mean storage duration of >14 days were included in longer-18 storage group. No recipients died within 2 weeks of transplantation. Recipients were followed 19 until death or the end of the study in September 2017 for a maximum of 5 years. All data 20 were derived from our institution's electronic medical records and prospectively collected 21 liver transplantation database. The institutional review board (SMC 2017-05-013) approved 22 this retrospective cohort study and waived the requirement for written informed consent. 
Operative management
Acceptance criteria for liver donation were ≤65 years, body mass index <35 kg/m 2 , 1 macrosteatosis degree ≤30%, and residual liver volume ≥30%. All grafts consisted of 2 segment 5-8 excluding the middle hepatic vein trunk. Graft implantation was performed 3 using the piggyback technique. After portal vein anastomosis, the graft was reperfused by 4 consecutively unclamping the hepatic vein and portal vein. Hepatic artery anastomosis was 5 then performed, followed by biliary anastomosis. Immunosuppression was performed using 6 methylprednisolone, basiliximab, and mycophenolate mofetil in addition to tacrolimus. 21
7
Tacrolimus treatment was initiated on postoperative day 3, with a trough plasma 8 concentration of 10 ng/mL maintained during the first month and a concentration of 5-8 9 ng/mL maintained thereafter. Hepatitis B virus (HBV) prophylaxis was performed using Canada). The irradiation duration was modified based on dose distribution mapping performed by outside experts so that the absorbed-dose at the center of the target was 25 Gy, 1 with a minimum of >15 Gy and maximum of <50 Gy throughout the target (Supplementary 2 Fig. S1 ). The use of RBCs stored for >24 hours after irradiation was prohibited because of 3 concerns of massive RBC storage lesion (e.g. hyperkalemia) without the consideration of 4 plasma washing. 23 Compatibility was routinely evaluated using ABO/Rh typing, testing 5 recipient serum for clinically important alloantibodies, and serologically cross-matching 6 donor RBCs with recipient serum. Our blood bank delivered RBCs to the operating room 7 using the first-in-first-out principle to consume older RBCs before newer one. 6 8 9 Transfusion policy 10 The transfusion policy of our transplant team is characterized by restrictive and prophylactic 11 use of blood products. 3, 6, 22 Each blood component was separately transfused based on its 12 respective indication. The trigger for allogeneic RBC transfusion was hemoglobin 8.0 g/dL.
13
Blood salvage was routinely used for autologous RBC transfusion, with salvaged RBCs being 14 used first when RBC transfusion was indicated. A leukocyte depletion filter was routinely 15 used before autotransfusion for HCC patients. 3 Use of fresh frozen plasma was indicated 16 when the prothrombin time international normalized ratio was >3.0. Platelet transfusion was 17 indicated when the platelet count decreased to <30×10 9 /L. Cryoprecipitate was indicated 18 when the fibrinogen level was <80 mg/dL. Korean national policy limits storage of RBCs, 19 platelets, fresh frozen plasma, and cryoprecipitate to 35 days, 5 days, 1 year, and 1 year, 20 respectively. The RBCs, platelets, fresh frozen plasma, and cryoprecipitate were stored at 1-6, 21 22-26, <-20, and <-20˚C, respectively.
Variables and statistical analyses 24
The primary outcome was post-transplant death. Survival analyses were performed using the Cox model, and the results are described using hazard ratio (HR) and 95% confidence 1 interval. The backward selection process was performed for all variables evaluated during the 2 univariable analyses to generate a multivariable model, using p < 0.05 for the inclusion of 
RESULTS

22
Among the 1,349 RBC units transfused into the 200 recipients during the 2-week period, 832 23 units were stored for 4-10 days, and 517 units were stored for >14 days (Fig. 1 were higher in longer-storage group. The proportion of recipients who underwent 9 transplantation during the post-storage leukoreduction period (the earlier period) was 10 significantly greater in shorter-storage group, indicating that RBC storage duration increased 11 over time in relation to increased blood stock in our hospital blood bank: 5 mean storage 12 duration of RBCs was 9 (7-14) days during the post-storage leukoreduction period and 15 13 (12-19) days during the pre-storage leukoreduction period. As shown in Table 1 , there were 14 no significant differences between the two groups regarding donor/recipient age, 15 donor/recipient gender, macrosteatosis, graft-to-recipient weight ratio, graft ischemia time, 16 donor-recipient ABO blood type compatibility, body mass index, etiology of liver disease, 17 model for end-stage liver disease score, HCC, platelet count, ascites, encephalopathy, or 18 hepatorenal syndrome (p > 0.05). Operation time was longer by 31 minutes in longer-storage 19 group (578 vs. 547 minutes, p = 0.010). The incidence of intraoperative abrupt massive 20 bleeding was comparable (p > 0.99). The amounts of transfused fresh frozen plasma, platelet 21 concentrates, and cryoprecipitate did not differ significantly between the two groups (p > 22 0.05).
23
After a median follow-up of 60 months, 27 recipients (13.5%) had died. The continuous 24 value of mean RBC storage duration was not associated with death risk (HR=1.01 [0.94-exclusion of recipients with mean RBC storage duration of 10-14 days was not significant 23 ( Supplementary Fig. S2A ). In addition, 241 recipients were stratified into four groups based 24 on RBC storage quartile strata (4-7 days, n=59; >7 days and ≤10 days, n=66; >10 days and ≤16 days, n=68; and >16 days, n=48). The mean storage duration of each group was 6 (5-7), Donated RBCs can be stored for as long as 42 days before transfusion, based on the 23 survival of one-quarter of the transfused RBCs during 1 day after transfusion; 2,12 however, 24 one concern is the uncertainty of clinically significant impacts of transfusing older RBCs Grade II to III 14 (11.9) 9 (11.0) 0.846
Surgical site bleeding 6 (5.1) 9 (11.0) 0.120
Surgical site infection 5 (4.2) 4 (4.9) >0.99
Graft rejection 10 (8.5) 10 (12.2) 0.388
Data are presented as median (25th percentile, 75th percentile) or frequency (%). AST, aspartate 3 transaminase; ALT, alanine transaminase.
